+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Wet Age - Related Macular Degeneration (Wet AMD) - Epidemiology Forecast to 2030

  • ID: 5292796
  • Report
  • February 2021
  • Region: Global
  • 65 pages
  • DelveInsight
This ‘Wet-Age-related Macular Degeneration (Wet-AMD) - Epidemiology Forecast - 2030’ report delivers an in-depth understanding of the Wet-AMD, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Wet-AMD Disease Understanding

Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries worldwide, profoundly affecting the quality of life of affected individuals. The increase in life expectancy bringing growth in the number of reported cases adds a significant burden on the health care systems with the expensive current standard of care. Wet-AMD is a type of AMD which is characterized by abrupt central vision loss caused by abnormal blood vessels that bleed or leak fluid, which may swell and damage the macula. Wet-AMD, also referred to as neovascular AMD, accounts for roughly 10% of AMD cases, but almost 90% of AMD-related central vision loss. Although 80% of the patients have non-neovascular or atrophic AMD, the disease's neovascular form is responsible for nearly 90% of the severe, central visual acuity loss associated with AMD.

AMD’s progression leads to loss of central vision, which adversely affects the quality of life. Although AMD’s exact functional pathogenesis is not fully understood, there have been recent improvements in genetic technologies leading to the identification of various polymorphisms that have shown to harbor unique AMD associations.

Wet-AMD Epidemiology

The Wet-AMD epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The total prevalent cases of Wet-AMD patients are increasing in 7MM during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Wet-AMD symptoms epidemiology segmented as the Total Prevalent cases of Wet-AMD, Gender-specific cases of Wet-AMD, and Age-specific cases of Wet-AMD. The report includes the prevalent scenario of Wet-AMD symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise - Wet-AMD Epidemiology

The epidemiology segment also provides the Wet-AMD epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent cases of Wet-AMD associated in 7MM countries were 4,426,968 in 2020.
  • As per the estimates, the United States has the largest prevalent population of Wet-AMD.
  • Among the EU5 countries, Germany had the highest prevalent cases of Wet-AMD, followed by Italy. On the other hand, Spain had the lowest prevalent cases with 300,552 cases in 2020.
Scope of the Report
  • The Wet-AMD report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • The Wet-AMD Epidemiology Report and Model provide an overview of Wet-AMD's risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into Wet-AMD's historical and forecasted patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Wet-AMD.
  • The report provides the segmentation of the Wet-AMD epidemiology by diagnosed prevalent cases of Wet-AMD in 7MM.
  • The report provides the segmentation of the Wet-AMD epidemiology by Gender-specific prevalent cases of Wet-AMD in 7MM.
  • The report provides the segmentation of the Wet-AMD epidemiology by Age-specific prevalent cases of Wet-AMD in 7MM.
Report Highlights
  • 11-year Forecast of Wet-AMD epidemiology
  • 7MM Coverage
  • Total Diagnosed Prevalent Cases of Wet-AMD
  • Prevalent Cases according to segmentation: Gender-specific cases of Wet-AMD
  • Prevalent Cases according to segmentation: Age-specific cases of Wet-AMD
KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate the secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM for the patient population about Wet-AMD?
  • What are the key findings of the Wet-AMD epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of Wet-AMD patients across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burden, and unmet needs of the Wet-AMD?
  • What are the currently available treatments for Wet-AMD?
Reasons to Buy

The Wet-AMD epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Wet-AMD market.
  • Quantify patient populations in the global Wet-AMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Wet-AMD therapeutics in each of the markets covered.
  • Understand the magnitude of the Wet-AMD population by its Total Prevalence cases.
  • Understand the magnitude of the Wet-AMD population by its Gender-specific cases.
  • Understand the magnitude of the Wet-AMD population by its Age-specific cases.
  • The Wet-AMD epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Wet-AMD Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period:
2017-2030

In the case of the United States, as per estimates, approximately 11 to 15 million people in the United States have AMD, and more than 1.7 million Americans have the advanced form of the disease. About 200,000 new cases of wet AMD are diagnosed each year in North America. Due to the aging population, the National Eye Institute estimates that the prevalence of advanced AMD will grow to nearly 3 million by 2020. Wet macular degeneration accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness. This assumption was particularly used to obtain the burden of Wet-AMD among the prevalent AMD population. Age is a prominent risk factor for Age-related macular degeneration. The risk of getting advanced age-related macular degeneration increase from 2% for those ages 50-59 to nearly 30% for those over the age of 75.

A recent study by the European Eye Epidemiology (E3) Consortium collated prevalence data of 14 European population studies and reported the prevalence of any AMD among adults aged 70 years and older to be 16.2% based on the Rotterdam classification. The authors extrapolated the number of Europeans with early and late AMD and predicted almost a doubling of AMD prevalence in Europe until 2040. Yet, until today, we lack pooled European estimates on AMD incidence.
Note: Product cover images may vary from those shown
1 Key Insights

2 Executive summary

3 Organizations

4 Wet Form Age-related Macular Degeneration (Wet-AMD): Market Overview at a Glance
4.1 Total Market Share (%) Distribution of Wet Form Age-related Macular Degeneration (Wet-AMD) in 2017
4.2 Total Market Share (%) Distribution of Wet Form Age-related Macular Degeneration (Wet-AMD) in 2030

5 Wet Form Age-related Macular Degeneration (Wet-AMD): Market Overview at a Glance
5.1 Introduction
5.2 Classification and clinical manifestations
5.3 Signs and Symptoms
5.4 Risk factors
5.5 Pathophysiology
5.6 Diagnosis
5.6.1 Patients' history, clinical examination, and self-monitoring
5.6.2 Angiography
5.6.3 Optical coherence tomography (OCT)

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Assumptions and Rationale
6.3 Total cases of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM
6.4 United States
6.4.1 Total prevalent cases of Wet-AMD in the United States
6.4.2 Gender-specific cases of Wet-AMD in the United States
6.4.3 Age-specific cases of Wet-AMD in the United States
6.5 EU5 Countries
6.6 Germany
6.6.1 Total prevalent cases of Wet-AMD in Germany
6.6.2 Gender-specific cases of Wet-AMD in Germany
6.6.3 Age-specific cases of Wet-AMD in Germany
6.7 France
6.7.1 Total prevalent cases of Wet-AMD in France
6.7.2 Gender-specific cases of Wet-AMD in France
6.7.3 Age-specific cases of Wet-AMD in France
6.8 Italy
6.8.1 Total prevalent cases of Wet-AMD in Italy
6.8.2 Gender-specific cases of Wet-AMD in Italy
6.8.3 Age-specific cases of Wet-AMD in Italy
6.9 Spain
6.9.1 Total prevalent cases of Wet-AMD in Spain
6.9.2 Gender-specific cases of Wet-AMD in Spain
6.9.3 Age-specific cases of Wet-AMD in Spain
6.10. UK
6.10.1 Total prevalent cases of Wet-AMD in the United Kingdom
6.10.2 Gender-specific cases of Wet-AMD in the United Kingdom
6.10.3 Age-specific cases of Wet-AMD in the United Kingdom
6.11 Japan
6.11.1 Total prevalent cases of Wet-AMD in Japan
6.11.2 Gender-specific cases of Wet-AMD in Japan
6.11.3 Age-specific cases of Wet-AMD in Japan

7 KOL Views

8 Bibliography

9 Appendix
9.1 Report Methodology

10 Publisher Capabilities

11 Disclaimer

12 About the Publisher

List of Tables
Table 1: Summary of Wet-AMD Market, Epidemiology, and Key Events (2017-2030)
Table 2: Total cases of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM (2017-2030)
Table 3: Total prevalent cases of Wet-AMD in the United States (2017-2030)
Table 4: Gender-specific cases of Wet-AMD in the US (2017-2030)
Table 5: Age-specific cases of Wet-AMD in the US (2017-2030)
Table 6: Total prevalent cases of Wet-AMD in Germany (2017-2030)
Table 7: Gender-specific cases of Wet-AMD in Germany (2017-2030)
Table 8: Age-specific cases of Wet-AMD in Germany (2017-2030)
Table 9: Total prevalent cases of Wet-AMD in France (2017-2030)
Table 10: Gender-specific cases of Wet-AMD in France (2017-2030)
Table 11: Age-specific cases of Wet-AMD in France (2017-2030)
Table 12: Total prevalent cases of Wet-AMD in Italy (2017-2030)
Table 13: Gender-specific cases of Wet-AMD in Italy (2017-2030)
Table 14: Age-specific cases of Wet-AMD in Italy (2017-2030)
Table 15: Total prevalent cases of Wet-AMD in Spain (2017-2030)
Table 16: Gender-specific cases of Wet-AMD in Spain (2017-2030)
Table 17: Age-specific cases of Wet-AMD in Spain (2017-2030)
Table 18: Total prevalent cases of Wet-AMD in the United Kingdom (2017-2030)
Table 19: Gender-specific cases of Wet-AMD in the UK (2017-2030)
Table 20: Age-specific cases of Wet-AMD in the UK (2017-2030)
Table 21: Total prevalent cases of Wet-AMD in Japan (2017-2030)
Table 22: Gender-specific cases of Wet-AMD in Japan (2017-2030)
Table 23: Age-specific cases of Wet-AMD in Japan (2017-2030)

List of Figures
Figure 1: Mechanism of action of CFH (in normal regulation)
Figure 2: Total cases of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM (2017-2030)
Figure 3: Total prevalent cases of Wet-AMD in the United States (2017-2030)
Figure 4: Gender-specific cases of Wet-AMD in the US (2017-2030)
Figure 5: Age-specific cases of Wet-AMD in the US (2017-2030)
Figure 6: Total prevalent cases of Wet-AMD in Germany (2017-2030)
Figure 7: Gender-specific cases of Wet-AMD in Germany (2017-2030)
Figure 8: Age-specific cases of Wet-AMD in Germany (2017-2030)
Figure 9: Total prevalent cases of Wet-AMD in France (2017-2030)
Figure 10: Gender-specific cases of Wet-AMD in France (2017-2030)
Figure 11: Age-specific cases of Wet-AMD in France (2017-2030)
Figure 12: Total prevalent cases of Wet-AMD in Italy (2017-2030)
Figure 13: Gender-specific cases of Wet-AMD in Italy (2017-2030)
Figure 14: Age-specific cases of Wet-AMD in Italy (2017-2030)
Figure 15: Total prevalent cases of Wet-AMD in Spain (2017-2030)
Figure 16: Gender-specific cases of Wet-AMD in Spain (2017-2030)
Figure 17: Age-specific cases of Wet-AMD in Spain (2017-2030)
Figure 18: Total prevalent cases of Wet-AMD in the United Kingdom (2017-2030)
Figure 19: Gender-specific cases of Wet-AMD in the UK (2017-2030)
Figure 20: Age-specific cases of Wet-AMD in the UK (2017-2030)
Figure 21: Total prevalent cases of Wet-AMD in Japan (2017-2030)
Figure 22: Gender-specific cases of Wet-AMD in Japan (2017-2030)
Figure 23: Age-specific cases of Wet-AMD in Japan (2017-2030)
Note: Product cover images may vary from those shown
Adroll
adroll